Revista complutense de educación

Resumen basado en el de la publicaciónCada sociedad define superdotación según las posibilidades y necesidades, y por eso el concepto puede variar de acuerdo con el lugar y el tiempo. Pero el entendimiento debe existir porque sin él se pueden perder y desperdiciar potenciales que son importantes en una sociedad o en otra.ES

Ser superdotado no es sólo ser inteligente, sino que también abarca aspectos sociales y emocionales.

Sin resume

Growing Up Amid Ethno‐Political Conflict: Aggression and Emotional Desensitization Promote Hostility to Ethnic Outgroups

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/134287/1/cdev12599.pdfhttp://deepblue.lib.umich.edu/bitstream/2027.42/134287/2/cdev12599_am.pd

Salmonella Type III Effector AvrA Stabilizes Cell Tight Junctions to Inhibit Inflammation in Intestinal Epithelial Cells

Salmonella Typhimurium is a major cause of human gastroenteritis. The Salmonella type III secretory system secretes virulence proteins, called effectors. Effectors are responsible for the alteration of tight junction (TJ) structure and function in intestinal epithelial cells. AvrA is a newly described bacterial effector found in Salmonella. We report here that AvrA expression stabilizes cell permeability and tight junctions in intestinal epithelial cells. Cells colonized with an AvrA-deficient bacterial strain (AvrA−) displayed decreased cell permeability, disruption of TJs, and an increased inflammatory response. Western blot data showed that TJ proteins, such as ZO-1, claudin-1, decreased after AvrA- colonization for only 1 hour. In contrast, cells colonized with AvrA-sufficient bacteria maintained cell permeability with stabilized TJ structure. This difference was confirmed in vivo. Fluorescent tracer studies showed increased fluorescence in the blood of mice infected with AvrA- compared to those infected with the AvrA-sufficient strains. AvrA- disrupted TJ structure and function and increased inflammation in vivo, compared to the AvrA- sufficient strain. Additionally, AvrA overexpression increased TJ protein expression when transfected into colonic epithelial cells. An intriguing aspect of this study is that AvrA stabilized TJs, even though the other TTSS proteins, SopB, SopE, and SopE2, are known to disrupt TJs. AvrA may play a role in stabilizing TJs and balancing the opposing action of other bacterial effectors. Our findings indicate an important role for the bacterial effector AvrA in regulation of intestinal epithelial cell TJs during inflammation. The role of AvrA represents a highly refined bacterial strategy that helps the bacteria survive in the host and dampen the inflammatory response

El valor de ser superdotado

Presenta un material de ayuda a padres, educadores y profesores de niños superdotados, útil para aprender a conocer las capacidades y las necesidades de estos niños. Los primeros capítulos analizan el desarrollo personal y afectivo de los superdotados, las cualidades y los problemas existenciales que les plantea su personalidad. Después analiza el talento y la creatividad como un elemento necesario en la educación de estos niños y expone distintas formas de educar la creatividad, utilizando como ejemplo la experiencia educativa que la autora ha tenido en el Instituto para el Fomento de las Ciencias y las Artes para los Niños y Jóvenes con los niños superdotados.MadridES

Effects of Supplementation on Juniper Intake by Goats

The potential for winter supplementation to increase juniper intake by goats on rangelands in the Edwards Plateau region of Texas was assessed in two experiments. The first experiment evaluated the effect on juniper intake of either no supplementation (negative control) or supplementation with corn, alfalfa, or cottonseed meal fed at an isonitrogenous protein level of 1.5 g kg body weight-1 for 12 days. Redberry juniper (Juniperus pinchotii Sudw.) consumption by individually penned Spanish, Boer 3 Spanish, Spanish 3 Angora, and Angora goats was measured on days 11 and 12. Each goat received each supplement in a complete 4 X 4 Latin square design. Juniper intake increased for goats supplemented with alfalfa and cottonseed meal (P = 0.001), but not for those supplemented with corn (P = 0.944). Boer 3 Spanish goats did not differ in levels of consumption (P = 0.085) from the other breeds. A second study investigated the effect of either no supplementation or soybean meal supplementation on juniper consumption by free grazing Angora and Boer 3 Spanish goats. Forty goats were assigned to four pasture groups by breed and previous juniper intake, and randomly allocated to either the treatment (supplementation) or control (no supplementation) regime in a complete block design. After 4 days of grazing and supplementation, fecal samples were collected to estimate percent of juniper in the diet using near-infrared spectroscopy. Goats were then rotated to another pasture. Juniper intake was highest for goats supplemented with soybean meal (P = 0.034). Breed of goat did not affect intake (P = 0.240). Goats previously categorized as high juniper consumers based upon prior measurements of juniper intake ate more juniper (P = 0.003) than those classified as low consumers. This research indicates that the effectiveness of goats for biological control of juniper can be improved with a high protein, low starch supplement. The Rangeland Ecology & Management archives are made available by the Society for Range Management and the University of Arizona Libraries. Contact [email protected] for further information.Migrated from OJS platform August 202

MAGE-A3 or NY-ESO1 Expression and Spontaneous Antibody Responses to NY-ESO1 in Newly Diagnosed Multiple Myeloma Patients Are Associated with Worse Overall Survival

Abstract The cancer-testis antigens (CTA) are highly immunogenic antigens expressed in various tumors but not in normal tissues (except during gametogenesis), making them an attractive target for cancer immunotherapy. Expression of CTAs such as MAGE-A3, MAGE-C1 (CT7), MAGE-C2 (CT10), NY-ESO1 and the SSX antigens has been previously reported in multiple myeloma (MM). To date, however, these reports have included a heterogeneous group of newly diagnosed and relapsed/refractory patients, all in different stages of treatment. Therefore, the extent and prognostic significance of CTA expression, and of de novo immune responses against CTA in newly-diagnosed MM patients are not known. We now report on both CTA expression and antibody responses in MM patients at diagnosis and on their prognostic significance. From 8/00-11/04, we treated 67 newly-diagnosed, symptomatic patients with a thalidomide, doxorubicin, and dexamethasone-based induction regimen. (Brit J Haematol2006;132:155). Median age was 58; 54% were ISS stage I, 28% ISS II, and 18% ISS III. Nine of 63 tested (14%) had deletion 13q by FISH, while 24% had soft tissue involvement by MM. Responses to induction therapy included 10 (15%) CR, 16 (24%) VGPR, 26 (39%) PR, 6 (8%) stable or progressive disease, and 9 (13%) inevaluable. Post-induction 54 underwent autoSCT and 9 also underwent alloSCT.. Median overall survival (OS) has not been reached with 61% alive at median follow up of 65 months. Cryopreserved pre-treatment bone marrow plasma cells were used to assess CTA expression by RT-PCR. Pre- and post-treatment sera were used to assess antibody (Ab) responses against CTA proteins by ELISA. Fifty-two patients had sufficient RNA for PCR, and 46 had baseline serum for ELISA. OS of these groups did not differ significantly from the entire cohort. At least 1 CTA was expressed in 77% of cases, including MAGE-A3 (52%), SSX1 (40%), CT7 (29%), CT10 (25%), NY-ESO1 (21%), and SSX5 (17%). Three or more CTA were expressed in 29% of cases. Individually MAGE-A3 or NY-ESO1 expression at diagnosis conferred a poorer prognosis (MAGE-A3: median OS 66 mos. vs. not reached, p=0.02 by log-rank; NY-ESO1: median OS 65 mos. vs. not reached, p=0.09). These poorer outcomes were independent of ISS stage, presence of del 13q, or response to induction therapy. No other CTA was associated with an OS difference, nor was the total number of CTA expressed prognostically significant. Baseline Ab responses, all at titers > 1:1600, were noted to NY-ESO1 in 6/46 (13%) patients, 5 of whom also had Ab to the NY-ESO1 homologue LAGE-1. Ab responses were also noted to CT7 (n=2), CT10 (n=1) and SSX4 (n=1). No Ab responses were noted to MAGE-A3. The effect of induction therapy on antibody titers was inconsistent, with increases, decreases, and no changes seen. Interestingly, 2 of the 6 NY-ESO1 Ab+ patients had no NY-ESO1 expression in bone marrow plasma cells. Both, however, had extensive soft tissue (ST) plasmacytomas, suggesting another source of NY-ESO1 antigen. Presence of NY-ESO1 Ab correlated significantly with baseline ST involvement, with 67% of Ab+ patients having ST disease compared with 20% of Ab− patients (p=0.05). NY-ESO1 Ab+ patients also had significantly poorer OS (med 21 mos. vs. not reached, p=0.009), independent of other prognostic factors. In sum, CTA expression is frequent in newly diagnosed MM patients, and expression of MAGE-A3 or NY-ESO1 is associated with worse long-term survival. Spontaneous antibody responses against NY-ESO1 are seen in untreated patients, and are associated with ST involvement and poorer survival. Further exploration of biologic differences between CTA+ and CTA-MM, as well as immunotherapeutic strategies which target these antigens, are warranted